For this reason, we conducted a retrospective study to assess the association between clinical response and overall survival (OS) and the most common blood-based inflammation biomarkers like NLR, platelet to lymphocyte ratio (PLR), neutrophil to monocyte ratio (NMR), monocyte to lymphocyte ratio (MLR), the systemic inflammation index (SII), and the aggregate index of systemic inflammation (AISI), in patients with advanced-stage NSCLC and PD-L1 tumor proportion score (TPS) lower than 50% who underwent first-line chemoimmunotherapy. Here, CD274 is linked to non-small cell lung carcinoma.